Victoza(liraglutide)
Saxenda, Victoza, Xultophy (liraglutide) is a protein pharmaceutical. Liraglutide was first approved as Victoza on 2009-06-30. It has been approved in Europe to treat obesity, overweight, and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Liraglutide, Saxenda, Victoza
CombinationsXultophy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin degludec
+
Liraglutide
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Xultophy 100/3.6 | insulin degludec and liraglutide | Novo Nordisk | N-208583 RX | 2016-11-21 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| liraglutide | ANDA | 2025-01-13 |
| saxenda | New Drug Application | 2024-11-01 |
| victoza | New Drug Application | 2024-11-01 |
| xultophy 100/3.6 | Biologic Licensing Application | 2024-11-01 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LIRAGLUTIDE RECOMBINANT, SAXENDA, NOVO | |||
| 2023-12-04 | NPP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Liraglutide Recombinant, Saxenda, Novo | |||
| 9968659 | 2037-01-09 | U-2313, U-2438 | |
| 9132239 | 2032-02-01 | DP | |
| 9457154 | 2027-09-27 | DP | |
| 9687611 | 2027-02-27 | DP | |
| RE46363 | 2026-08-03 | DP | |
| 8920383 | 2026-07-17 | DP | |
| 9775953 | 2026-07-17 | DP | |
| 10220155 | 2026-07-17 | DP | |
| 11097063 | 2026-07-17 | DP | |
| 9108002 | 2026-01-26 | DP | |
| 9616180 | 2026-01-20 | DP | |
| 9861757 | 2026-01-20 | DP | |
| 10357616 | 2026-01-20 | DP | |
| 10376652 | 2026-01-20 | DP | |
| 11311679 | 2026-01-20 | DP | |
| 8684969 | 2025-10-20 | DP | |
| 11446443 | 2025-10-20 | DP | |
| 8114833 | 2025-08-13 | DS, DP | |
| 7762994 | 2024-05-23 | DP | |
| 8579869 | 2023-06-30 | DP | |
| Liraglutide Recombinant, Victoza, Novo Nordisk Inc | |||
| 9265893 | 2032-09-23 | DP | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AE: Insulins and analogues for injection, long-acting
— A10AE56: Insulin degludec and liraglutide
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BJ: Glucagon-like peptide-1 (glp-1) analogues
— A10BJ02: Liraglutide
HCPCS
No data
Clinical
Clinical Trials
493 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 34 | 16 | 53 | 16 | 24 | 142 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 19 | 13 | 49 | 19 | 24 | 123 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 7 | 5 | 12 | 7 | 7 | 38 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 3 | 4 | 1 | 1 | 10 |
| Weight loss | D015431 | HP_0001824 | — | — | 2 | 1 | 1 | 3 | 7 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 2 | 3 | — | 5 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 1 | 2 | — | 3 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | 2 | — | 3 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | 3 | — | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 2 | — | 2 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nutrition disorders | D009748 | EFO_0001069 | — | 7 | 2 | 8 | — | 1 | 18 |
| Overweight | D050177 | — | E66.3 | 3 | 1 | 4 | — | 3 | 11 |
| Body weight | D001835 | EFO_0004338 | — | — | 2 | 3 | — | — | 5 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | 2 | — | — | 3 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | 1 | — | — | 2 |
| Bulimia | D002032 | — | F50.2 | — | — | 1 | — | — | 1 |
| Feeding and eating disorders | D001068 | — | F50 | — | — | 1 | — | — | 1 |
| Binge-eating disorder | D056912 | — | F50.2 | — | — | 1 | — | — | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | 1 | — | — | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tobacco use disorder | D014029 | — | F17 | — | 1 | — | — | — | 1 |
| Smoking cessation | D016540 | EFO_0004319 | — | — | 1 | — | — | — | 1 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 1 | — | — | — | 1 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | 1 | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
| Pouchitis | D019449 | EFO_0003921 | K91.850 | — | 1 | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 18 | — | — | — | — | 18 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | — | — | — | 1 | 1 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | — | — | — | 1 | 1 |
| Neuroendocrine carcinoma | D018278 | — | — | — | — | — | — | 1 | 1 |
| Papillary thyroid cancer | D000077273 | — | — | — | — | — | — | 1 | 1 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | — | — | — | 1 | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 1 | 1 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Liraglutide |
| INN | liraglutide |
| Description | Liraglutide is a lipopeptide that is an analogue of human GLP-1 in which the lysine residue at position 27 is replaced by arginine and a hexadecanoyl group attached to the remaining lysine via a glutamic acid spacer. Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has a role as a glucagon-like peptide-1 receptor agonist and a neuroprotective agent. It is a lipopeptide and a polypeptide. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 204656-20-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4524066 |
| ChEBI ID | — |
| PubChem CID | 16134956 |
| DrugBank | DB06655 |
| UNII ID | 839I73S42A (ChemIDplus, GSRS) |
Target
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Saxenda – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Xultophy – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Victoza – Novo Nordisk
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Liraglutide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,737 documents
View more details
Safety
Black-box Warning
Black-box warning for: Liraglutide, Saxenda, Victoza, Xultophy 100/3.6
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
39,386 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use